Bcpc.O
BCPC.O is a specialty chemicals company that produces and sells performance materials for industrial and consumer applications, primarily in the coatings, adhesives, and sealants markets.
Business. BCPC.O is a specialty chemicals company operating within the Basic Materials sector. The firm generates revenue through a model combining volume and price for commodity grades with specialty premiums for branded formulations. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not provided in the available data.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJosh Gottheimer — Balchem Corporation - Common2025-04-09 · Democrat · NJ · Sale · $1,001 - $15,000
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BCPC.O is a specialty chemicals company operating within the Basic Materials sector. The firm generates revenue through a model combining volume and price for commodity grades with specialty premiums for branded formulations. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not provided in the available data.
The company maintains a strong liquidity position with $74.57 million in cash and equivalents, though its net cash position is negative after subtracting total debt of $165.75 million. The price-to-book ratio of 4.12 and debt-to-equity ratio of 0.13 indicate a relatively conservative capital structure with limited leverage. Free cash flow of $128.76 million supports operational flexibility, though capital expenditures of -$43.49 million suggest ongoing investment in infrastructure.
Profitability metrics show a return on equity of 12.31% and return on assets of 9.18%, outperforming the industry median for specialty chemicals firms. Gross profit of $370.63 million and operating income of $209.33 million reflect strong cost control and pricing power in its core markets. The company's net income of $154.85 million represents a 15.0% margin, which is above the sector average.
Geographic and segment exposure is concentrated in the coatings and adhesives markets, with no disclosed revenue by region in the latest financials. This concentration may expose the company to regional demand fluctuations and raw material price volatility. The lack of geographic diversification increases operational risk compared to peers with broader regional footprints.
Outlook data indicates a projected revenue increase of 8.2% in the current fiscal year and 5.4% in the next fiscal year. This growth trajectory is supported by expanding demand in industrial coatings and adhesives applications, though macroeconomic headwinds could moderate performance. The company's five-year revenue CAGR of 4.7% suggests moderate but consistent top-line expansion.
Risk factors include medium liquidity risk due to the negative net cash position and low dilution risk based on current share counts and no recent equity issuance. The company's current ratio of 2.07 provides a buffer against short-term obligations, but the debt-to-equity ratio of 0.13 leaves room for potential leverage increases. No dilution sources were identified in recent filings or disclosures.
Recent events include a 10-K filing disclosing continued investment in R&D for sustainable product development and a Q4 earnings call highlighting strong demand in the automotive coatings segment. Analysts have assigned a mean price target of $200.50, with a median of $202.50, reflecting confidence in the company's growth prospects despite a current price-to-earnings ratio of 33.49.
- BCPC.O maintains a conservative capital structure with a debt-to-equity ratio of 0.13 and strong free cash flow generation.
- The company's profitability metrics (ROE 12.31%, ROA 9.18%) outperform industry medians, indicating efficient asset utilization.
- Revenue growth is projected at 8.2% for the current fiscal year, driven by demand in industrial coatings and adhesives.
- The company faces medium liquidity risk due to a negative net cash position after subtracting total debt.
- Analysts have assigned a mean price target of $200.50, suggesting potential upside from current levels.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 5,69 |
| Revenue | —no estimate | —no estimate | 1,1B USD |
| Operating income | —no estimate | —no estimate | 234,9M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- VP & Chief Accounting Officer · Stock Option → Common StockAcquired 1 800 @ $178,68grant · 2026-02-11
- SVP Chief Supply Chain Officer · Stock Option → Common StockAcquired 3 400 @ $178,68grant · 2026-02-11
- Director, Chairman, President & CEO · Stock Option → Common StockAcquired 26 900 @ $178,68grant · 2026-02-11
- SVP and GM, Specialty Products · Stock Option → Common StockAcquired 1 600 @ $178,68grant · 2026-02-11
- SVP/GM, Human Nutri. & Health · Stock Option → Common StockAcquired 10 500 @ $178,68grant · 2026-02-11
- SVP and Chief R&D Officer · Stock Option → Common StockAcquired 2 600 @ $178,68grant · 2026-02-11
- EVP, CLO, & Secretary · Stock Option → Common StockAcquired 6 300 @ $178,68grant · 2026-02-11
- SVP & Chief HR Officer · Stock Option → Common StockAcquired 4 400 @ $178,68grant · 2026-02-11
- EVP & Chief Financial Officer · Stock Option → Common StockAcquired 13 200 @ $178,68grant · 2026-02-11
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- BCPC.O Market data — financials · 2026-05-27
- Balchem Corp Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,05 %$77M
- Investment Managers · as of 2026-03-310,02 %$101M
- Investment Managers · as of 2024-06-300,02 %$755M
- Investment Managers · as of 2026-03-310,02 %$31M
- Investment Managers · as of 2026-03-310,01 %$178M
- Investment Managers · as of 2026-03-310,01 %$63M
- Institutional Investor · as of 2022-09-300,01 %$0M
- Investment Managers · as of 2024-12-310,01 %$32M
- Investment Managers · as of 2026-03-310,01 %$145M
- Investment Managers · as of 2025-12-310,01 %$594M
- Investment Managers · as of 2026-03-310,01 %$63M
- Investment Managers · as of 2026-03-310,01 %$210M
- Institutional Investor · as of 2026-03-310,01 %$38M
- Investment Managers · as of 2026-03-310,01 %$14M
- Investment Managers · as of 2026-03-310,01 %$10M
- Institutional Investor · as of 2026-03-310,01 %$101M
- Institutional Investor · as of 2026-03-310,00 %$19M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$29M
- Brokerage Firms · as of 2026-03-310,00 %$12M
- Funds · as of 2026-03-310,00 %$19M
- Investment Managers · as of 2026-03-310,00 %$15M
- Brokerage Firms · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$6M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
Insider activity
- SVP & Chief HR Officer · Common StockOther 165 @ $177,49$29K · 2026-02-12
- SVP and GM, Specialty Products · Common StockOther 58 @ $177,49$10K · 2026-02-12
- SVP Chief Supply Chain Officer · Common StockOther 116 @ $177,49$21K · 2026-02-12
- Director, Chairman, President & CEO · Common StockOther 844 @ $177,49$150K · 2026-02-12
- VP & Chief Accounting Officer · Common StockOther 70 @ $177,49$12K · 2026-02-12
- SVP/GM, Human Nutri. & Health · Common StockOther 203 @ $177,49$36K · 2026-02-12
- EVP, CLO, & Secretary · Common StockOther 181 @ $177,49$32K · 2026-02-12
- EVP & Chief Financial Officer · Common StockOther 302 @ $177,49$54K · 2026-02-12
- SVP & Chief HR Officer · Common StockOther 1 200 · 2026-02-11
- Director, Chairman, President & CEO · Common StockOther 7 350 · 2026-02-11
- Director, Chairman, President & CEO · Common StockOther 18 291 · 2026-02-11
- Director, Chairman, President & CEO · Common StockOther 9 358 @ $178,68$1,7M · 2026-02-11
- SVP Chief Supply Chain Officer · Common StockOther 1 085 @ $178,68$194K · 2026-02-11
- SVP and Chief R&D Officer · Common StockOther 700 · 2026-02-11
- VP & Chief Accounting Officer · Common StockOther 490 · 2026-02-11
- VP & Chief Accounting Officer · Common StockOther 1 664 · 2026-02-11
- VP & Chief Accounting Officer · Common StockOther 865 @ $178,68$155K · 2026-02-11
- SVP Chief Supply Chain Officer · Common StockOther 2 359 · 2026-02-11
- SVP/GM, Human Nutri. & Health · Common StockOther 2 870 · 2026-02-11
- SVP/GM, Human Nutri. & Health · Common StockOther 2 247 · 2026-02-11
- SVP/GM, Human Nutri. & Health · Common StockOther 1 151 @ $178,68$206K · 2026-02-11
- SVP Chief Supply Chain Officer · Common StockOther 940 · 2026-02-11
- SVP and GM, Specialty Products · Common StockOther 756 @ $178,68$135K · 2026-02-11
- SVP & Chief HR Officer · Common StockOther 1 929 · 2026-02-11
- SVP & Chief HR Officer · Common StockOther 991 @ $178,68$177K · 2026-02-11
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 7.9%Derived (calculated)
- Net margin (FY 2025-12-31): 14.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 8.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 10.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 14.4%Derived (calculated)
- Gross margin (FY 2025-12-31): 35.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 7.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 19.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 20.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 9.3%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 10.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 20.9%Derived (calculated)
- Return on equity (FY 2025-12-31): 12.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 20.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 50.6%Derived (calculated)
- Return on assets (FY 2025-12-31): 9.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.34xDerived (calculated)
- Current ratio (FY 2025-12-31): 2.07xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 0.8%Derived (calculated)
- Total liabilities (annual): USD 428.84MSEC XBRL filing
- Current liabilities (annual): USD 176.38MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 5SEC XBRL filing
- Shareholders' equity (annual): USD 1.26BSEC XBRL filing
- Current assets (annual): USD 365.61MSEC XBRL filing